In this video from the AAN Annual Virtual Meeting 2021, Dr. Susan Hutchinson talks about her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and […]
As many of you are aware, I was asked to go to India with a team of international headache experts to educate local providers. Each one of us on the team had a specific purpose and for me, it was to focus on the treatment of migraine in women. The need for good migraine management in India is great. With a population of over 1.3 billion, the estimated prevalence of migraine in India is over 150,000 million. By comparison, the prevalence of migraine in the United States is 38 million.
A newly formed non-profit healthcare organization in India has asked a small team of US physicians to lead the way in educating Primary Care Physicians and neurologists about migraine. Dr. Hutchinson’s focus will be the […]
Dr. Susan Hutchinson joined Dr. Jack Schim for a live Webcast on Thursday evening, October 25th, to discuss Ajovy, the second CGRP monoclonal Antibody approved for migraine prevention. It is an injection and offers the option of quarterly or monthly dosing.